Todd Hannigan, a director at IperionX Ltd (NASDAQ:IPX), reported a purchase of 225,225 ordinary shares on March 27, 2026, at a price of $3.20 per share. The transaction totaled approximately $721,000.
The insider acquisition takes place against a backdrop of notable share-price weakness. IPX shares have slid 53% over the past six months and are down 36% so far this year, with the stock quoted at $23.15 at the time of reporting.
Following the March 27 transaction, Hannigan's direct holdings in IperionX include 25,628,334 ordinary shares, plus 50,000 American Depositary Shares and 454,464 Restricted Stock Units. In addition, he holds performance rights tied to ordinary shares with strike references noted as A$6, A$7 and A$8 - specifically 306,302 rights at each of those levels.
On balance-sheet measures, the company is presented as solvent on a short-term basis with a current ratio of 4.03 and a cash position that exceeds its debt. Nonetheless, analysis from InvestingPro cited in available reporting indicates the stock looks overvalued relative to its Fair Value metrics at current levels.
Operationally, IperionX has begun commercial production at its Virginia facility. Management has set an output target of roughly 200 tonnes of titanium for this year, with plans to expand production to about 1,400 tonnes next year.
Analyst attention has accompanied these operational updates. BTIG commenced coverage with a Buy rating and a $40.00 price target. Separately, William Blair started coverage with an Outperform rating, highlighting the company's potential to grow into a leading domestic producer of titanium powder and noting its role in component manufacturing.
The reported insider purchase, substantial direct share ownership and the mix of operational progress and analyst initiation provide multiple angles for observers tracking IperionX. The company’s financial ratios and cash position are presented as strengths, while market valuation assessments and recent share-price declines reflect investor apprehension captured by available valuation metrics.
Summary
Todd Hannigan bought 225,225 ordinary shares of IperionX on March 27, 2026, at $3.20 per share for a total of approximately $721,000. He holds extensive direct and contingent positions in the company. IperionX has started commercial production in Virginia with staged output targets, and recent analyst initiations include Buy and Outperform ratings. The company reports a strong current ratio and more cash than debt, but a valuation service flagged the stock as overvalued. The share price has fallen significantly over recent periods and is trading at $23.15.